L
Louis P. Garrison
Researcher at University of Washington
Publications - 228
Citations - 6705
Louis P. Garrison is an academic researcher from University of Washington. The author has contributed to research in topics: Cost effectiveness & Health care. The author has an hindex of 41, co-authored 210 publications receiving 5607 citations. Previous affiliations of Louis P. Garrison include Hoffmann-La Roche & Mercer University.
Papers
More filters
Journal ArticleDOI
Donor Availability as the Primary Determinant of the Future of Heart Transplantation
TL;DR: Heart transplantation has now achieved a therapeutic status similar to that of cadaveric renal transplantation, and availability of heart donors was estimated based on data obtained on 1,955 organ donors in the United States.
Journal ArticleDOI
Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation Transmission Model
Beate Sander,Azhar Nizam,Louis P. Garrison,Maarten J. Postma,M. Elizabeth Halloran,Ira M. Longini +5 more
TL;DR: FTAP is an effective and cost-saving measure for mitigating pandemic influenza and in combination with school closure as well as prevaccination is the most effective single strategy.
Journal ArticleDOI
Good research practices for measuring drug costs in cost-effectiveness analyses
Louis P. Garrison,Edward C. Mansley,Thomas A. Abbott,Brian W. Bresnahan,Joel W. Hay,James E. Smeeding +5 more
TL;DR: This key recommendation is that current CEA practice acknowledge and embrace this limitation by adopting a new standard for the reference case as one of a "limited societal" or "health systems" perspective, using acquisition drug prices while including indirect costs and community preferences.
Journal ArticleDOI
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Jim Cassidy,Jean-Yves Douillard,Chris Twelves,Joseph McKendrick,Werner Scheithauer,Bustová I,Patrick G. Johnston,Lesniewski-Kmak K,S. Jelic,George Fountzilas,Fareeda Y. Coxon,Eduardo Díaz-Rubio,Tim Maughan,Malzyner A,Oscar Bertetto,Beham A,Arie Figer,Dufour P,Patel Kk,Cowell W,Louis P. Garrison +20 more
TL;DR: Cost savings and better outcomes make capecitabine a preferred adjuvant therapy for Dukes' C colon cancer, and this pharmacoeconomic analysis strongly supports replacing 5-FU/LV with cape citabine in the adjUvant treatment of colon cancer in the UK.
Journal ArticleDOI
Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer
Louis P. Garrison,Deborah P. Lubeck,Deepa Lalla,Virginia E. Paton,Amylou C. Dueck,Edith A. Perez +5 more
TL;DR: A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B‐31 and NCCTG N9831 trials.